<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04765787</url>
  </required_header>
  <id_info>
    <org_study_id>TSCL_NFORT-EFFECT_001</org_study_id>
    <nct_id>NCT04765787</nct_id>
  </id_info>
  <brief_title>Safety &amp; Efficacy of Nuberol Forte® in Pain Management</brief_title>
  <acronym>NFORT-EFFECT</acronym>
  <official_title>Clinical Response of Nuberol Forte® for the Pain Management in Musculoskeletal Disorders in Routine Pakistani Practice</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>The Searle Company Limited Pakistan</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>The Searle Company Limited Pakistan</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The global prevalence of Musculoskeletal disorders (MSD) ranges from 14% to as high as 42%.&#xD;
      In addition WHO also estimates that 40% of people over the age of 60 years suffer from MSD&#xD;
      and about 80% of the people have had low back pain at some point in their life. In Pakistan,&#xD;
      to estimate the prevalence of MSD, there is no data available based on the local population.&#xD;
      Locally, studies were conducted on the specific subject pools mainly considering the work&#xD;
      related musculoskeletal disorders and backache. However, no real data is available for the&#xD;
      symptomatic management of painful musculoskeletal disorders in multiple settings to calculate&#xD;
      more generalizable results. So this study is planned and if we found good results then it&#xD;
      will help physicians to prescribe the above said medicine to all such cases.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      The management of musculoskeletal pain is complex therefore plethora of treatment options are&#xD;
      available include non-pharmacological treatments , complementary therapies, and&#xD;
      pharmacological interventions. In order to provide optimal care to patients with&#xD;
      musculoskeletal pain and ensure the efficient use of healthcare resources, a comprehensive&#xD;
      overview of the available evidence for the most effective treatment options for&#xD;
      musculoskeletal pain presentations is essential. In this context, an observational study is&#xD;
      planned on the efficacy and safety of analgesic combination (i.e Nuberol Forte®). Nuberol&#xD;
      Forte® is a combination of muscle relaxant (Orphanedrine) and an analgesic/antipyretic&#xD;
      (Paracetamol/Acetaminophen). There are clear indications that the combination of Orphenadrine&#xD;
      with Paracetamol may give increased antinociceptive activity and duration of action over and&#xD;
      above the use of Orphenadrine or Paracetamol alone.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">November 25, 2020</start_date>
  <completion_date type="Actual">August 1, 2021</completion_date>
  <primary_completion_date type="Actual">April 1, 2021</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Cohort</observational_model>
    <time_perspective>Prospective</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>To assess the effectiveness of Nuberol Forte from baseline to 2 weeks</measure>
    <time_frame>2 weeks</time_frame>
    <description>the pain, muscle spasm and stiffness are assessed by Muscle &amp; Joint Measure scale.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>To assess the safety of Nuberol Forte in the cases presenting with Musculoskeletal disorder</measure>
    <time_frame>2 weeks</time_frame>
    <description>Safety is monitored from the first dose of the study drug</description>
  </primary_outcome>
  <number_of_groups>1</number_of_groups>
  <enrollment type="Actual">399</enrollment>
  <condition>Musculoskeletal Disorder</condition>
  <condition>Pain Management</condition>
  <arm_group>
    <arm_group_label>Painful musculoskeletal disorders in random order</arm_group_label>
    <description>Nuberol Forte® (Paracetamol 650 mg + Orphenadrine 50 mg) for the symptomatic management of the painful musculoskeletal disorders one tablet three times a day or as per physician discretion or as per severity of pain and treatment duration is 7-10 days</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Combination of Paracetamol 650mg + Orphenadrine 50mg</intervention_name>
    <description>In routine practice for pain , combination of Paracetamol 650 mg + Orphenadrine 50mg prescribed for 7-10 days with follow up and as per physician discretion</description>
    <arm_group_label>Painful musculoskeletal disorders in random order</arm_group_label>
    <other_name>Nuberol Forte</other_name>
  </intervention>
  <eligibility>
    <study_pop>
      <textblock>
        Pakistani patients suffering from painful musculoskeletal disorders includes ankle and knee&#xD;
        sprains, non-articular low-back pain, painful shoulder lesions (rotator cuff syndrome) and&#xD;
        a variety of occupational and sport injuries of the soft tissues in random order. In each&#xD;
        case, subjective measures of pain, muscle spasm, stiffness and other symptoms of the&#xD;
        musculoskeletal pain will be assessed through Muscle &amp; Joint Measure Scale (MJM). The&#xD;
        possible side-effects will be recorded along with other data.The physician will recruit the&#xD;
        musculoskeletal patients as per standard practice based on the medical judgment and after&#xD;
        review of subject's medical history, results of routine screening, physical and general&#xD;
        examination.&#xD;
      </textblock>
    </study_pop>
    <sampling_method>Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Patient with a clinical history of painful musculoskeletal disorder from last 1 year&#xD;
&#xD;
          -  Patient aged ≥18 and ≤70 years inclusive of either sex&#xD;
&#xD;
          -  Patient with ability to understand and sign written informed consent form.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Known hypersensitivity to Nuberol Forte product, the metabolites, or formulation&#xD;
             excipients.&#xD;
&#xD;
          -  Patients with Glaucoma, prostatic hypertrophy or obstruction at the bladder neck,&#xD;
             myasthenia gravis, oesophageal spasm and pyloric or duodenal obstruction.&#xD;
&#xD;
          -  Treated with Nuberol Forte to evaluate safety as per approved prescribing information&#xD;
             for Nuberol Forte in Pakistan.&#xD;
&#xD;
          -  Pregnant (assesed on LMP) or breast feeding women (assessed on interview).&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>70 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Asif Mahmood, Dr.</last_name>
    <role>Study Director</role>
    <affiliation>The Searle Company Limited</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Liaquat National Hospital</name>
      <address>
        <city>Karachi</city>
        <state>Sindh</state>
        <country>Pakistan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Medicare Hospital</name>
      <address>
        <city>Karachi</city>
        <state>Sindh</state>
        <country>Pakistan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Patel Hospital</name>
      <address>
        <city>Karachi</city>
        <state>Sindh</state>
        <country>Pakistan</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Pakistan</country>
  </location_countries>
  <link>
    <url>https://pubchem.ncbi.nlm.nih.gov/compound/1983</url>
    <description>National Center for Biotechnology Information. PubChem Database. Acetaminophen, CID=1983, (accessed on May 13, 2019)</description>
  </link>
  <link>
    <url>https://pubchem.ncbi.nlm.nih.gov/compound/4601</url>
    <description>National Center for Biotechnology; Information. PubChem Database. Orphenadrine, CID=4601 (accessed on May 13, 2019)</description>
  </link>
  <reference>
    <citation>Duffield SJ, Ellis BM, Goodson N, Walker-Bone K, Conaghan PG, Margham T, Loftis T. The contribution of musculoskeletal disorders in multimorbidity: Implications for practice and policy. Best Pract Res Clin Rheumatol. 2017 Apr;31(2):129-144. doi: 10.1016/j.berh.2017.09.004. Epub 2017 Nov 1. Review.</citation>
    <PMID>29224692</PMID>
  </reference>
  <reference>
    <citation>Palazzo C, Ravaud JF, Papelard A, Ravaud P, Poiraudeau S. The burden of musculoskeletal conditions. PLoS One. 2014 Mar 4;9(3):e90633. doi: 10.1371/journal.pone.0090633. eCollection 2014.</citation>
    <PMID>24595187</PMID>
  </reference>
  <reference>
    <citation>GBD 2016 Disease and Injury Incidence and Prevalence Collaborators. Global, regional, and national incidence, prevalence, and years lived with disability for 328 diseases and injuries for 195 countries, 1990-2016: a systematic analysis for the Global Burden of Disease Study 2016. Lancet. 2017 Sep 16;390(10100):1211-1259. doi: 10.1016/S0140-6736(17)32154-2. Erratum in: Lancet. 2017 Oct 28;390(10106):e38.</citation>
    <PMID>28919117</PMID>
  </reference>
  <reference>
    <citation>Babatunde OO, Jordan JL, Van der Windt DA, Hill JC, Foster NE, Protheroe J. Effective treatment options for musculoskeletal pain in primary care: A systematic overview of current evidence. PLoS One. 2017 Jun 22;12(6):e0178621. doi: 10.1371/journal.pone.0178621. eCollection 2017. Review.</citation>
    <PMID>28640822</PMID>
  </reference>
  <reference>
    <citation>Chou R, Peterson K, Helfand M. Comparative efficacy and safety of skeletal muscle relaxants for spasticity and musculoskeletal conditions: a systematic review. J Pain Symptom Manage. 2004 Aug;28(2):140-75. Review.</citation>
    <PMID>15276195</PMID>
  </reference>
  <reference>
    <citation>Straube A, Aicher B, Fiebich BL, Haag G. Combined analgesics in (headache) pain therapy: shotgun approach or precise multi-target therapeutics? BMC Neurol. 2011 Mar 31;11:43. doi: 10.1186/1471-2377-11-43. Review.</citation>
    <PMID>21453539</PMID>
  </reference>
  <reference>
    <citation>Høivik HO, Moe N. Effect of a combination of orphenadrine/paracetamol tablets ('Norgesic') on myalgia: a double-blind comparison with placebo in general practice. Curr Med Res Opin. 1983;8(8):531-5.</citation>
    <PMID>6653131</PMID>
  </reference>
  <reference>
    <citation>McGuinness BW. A double-blind comparison in general practice of a combination tablet containing orphenadrine citrate and paracetamol ('Norgesic') with paracetamol alone. J Int Med Res. 1983;11(1):42-5.</citation>
    <PMID>6219903</PMID>
  </reference>
  <reference>
    <citation>Hunskaar S, Donnell D. Clinical and pharmacological review of the efficacy of orphenadrine and its combination with paracetamol in painful conditions. J Int Med Res. 1991 Mar-Apr;19(2):71-87. Review.</citation>
    <PMID>1864455</PMID>
  </reference>
  <reference>
    <citation>Hawker GA, Mian S, Kendzerska T, French M. Measures of adult pain: Visual Analog Scale for Pain (VAS Pain), Numeric Rating Scale for Pain (NRS Pain), McGill Pain Questionnaire (MPQ), Short-Form McGill Pain Questionnaire (SF-MPQ), Chronic Pain Grade Scale (CPGS), Short Form-36 Bodily Pain Scale (SF-36 BPS), and Measure of Intermittent and Constant Osteoarthritis Pain (ICOAP). Arthritis Care Res (Hoboken). 2011 Nov;63 Suppl 11:S240-52. doi: 10.1002/acr.20543. Review.</citation>
    <PMID>22588748</PMID>
  </reference>
  <reference>
    <citation>Syrjala KL, Yi JC, Artherholt SB, Stover AC, Abrams JR. Measuring musculoskeletal symptoms in cancer survivors who receive hematopoietic cell transplantation. J Cancer Surviv. 2010 Sep;4(3):225-35. doi: 10.1007/s11764-010-0126-x. Epub 2010 May 8.</citation>
    <PMID>20454867</PMID>
  </reference>
  <reference>
    <citation>Hameed MH, Ghafoor R, Khan FR, Badar SB. Prevalence of musculoskeletal disorders among dentists in teaching hospitals in Karachi, Pakistan. J Pak Med Assoc. 2016 Oct;66(Suppl 3)(10):S36-S38.</citation>
    <PMID>27895349</PMID>
  </reference>
  <reference>
    <citation>Rathore FA, Attique R, Asmaa Y. Prevalence and Perceptions of Musculoskeletal Disorders Among Hospital Nurses in Pakistan: A Cross-sectional Survey. Cureus. 2017 Jan 26;9(1):e1001. doi: 10.7759/cureus.1001.</citation>
    <PMID>28280654</PMID>
  </reference>
  <verification_date>November 2021</verification_date>
  <study_first_submitted>February 19, 2021</study_first_submitted>
  <study_first_submitted_qc>February 19, 2021</study_first_submitted_qc>
  <study_first_posted type="Actual">February 21, 2021</study_first_posted>
  <last_update_submitted>November 8, 2021</last_update_submitted>
  <last_update_submitted_qc>November 8, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">November 10, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Musculoskeletal Disorder, Nuberol Forte, Pakistan</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Musculoskeletal Diseases</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Acetaminophen</mesh_term>
    <mesh_term>Orphenadrine</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

